Literature DB >> 27515517

The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer.

Hongjing Zang1, Weiyuan Wang1, Songqing Fan2.   

Abstract

PURPOSE: Non-small cell lung cancer (NSCLC), accounting for the most of lung cancers, is usually diagnosed in advanced stage. Targeted treatments boost advanced NSCLC patients with certain mutations, but early drug resistance blocks the advantages of target medicine. MicroRNAs (miRNAs) are regarded as a cluster of small noncoding and posttranscriptionally negative regulating RNAs. We want to explore the role of miRNAs in resistance to targeted treatments of NSCLC to improve the prognosis.
METHODS: We reviewed recent studies about miRNAs and targeted treatment resistance in NSCLC and classified resistance into two types: EGFR-TKIs resistance and ALK-TKIs resistance. RESULTS AND
CONCLUSION: Recent studies indicate that miRNAs involve in drug resistance possession in positive and negative manners. Inhibiting expression of certain miRNAs that promote drug resistance and increasing expression of miRNAs that reverse drug resistance may illuminate novel prospect of adjuvant targeted treatments in NSCLC.

Entities:  

Keywords:  Drug resistance; EGFR; MicroRNAs; NSCLC; Targeted treatment

Mesh:

Substances:

Year:  2016        PMID: 27515517     DOI: 10.1007/s00280-016-3130-7

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  17 in total

Review 1.  MicroRNAs: A novel potential biomarker for diagnosis and therapy in patients with non-small cell lung cancer.

Authors:  Qun Zhou; Shao-Xin Huang; Feng Zhang; Shu-Jun Li; Cong Liu; Yong-Yong Xi; Liang Wang; Xin Wang; Qi-Qiang He; Cheng-Cao Sun; De-Jia Li
Journal:  Cell Prolif       Date:  2017-10-08       Impact factor: 6.831

Review 2.  An Analysis of Mechanisms for Cellular Uptake of miRNAs to Enhance Drug Delivery and Efficacy in Cancer Chemoresistance.

Authors:  Justine M Grixti; Duncan Ayers; Philip J R Day
Journal:  Noncoding RNA       Date:  2021-04-16

Review 3.  The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications.

Authors:  Hongmei Zheng; Yuting Zhan; Sile Liu; Junmi Lu; Jiadi Luo; Juan Feng; Songqing Fan
Journal:  J Exp Clin Cancer Res       Date:  2018-09-14

Review 4.  The Antitumor Activities of Marsdenia tenacissima.

Authors:  Xiang Wang; Yuanliang Yan; Xi Chen; Shuangshuang Zeng; Long Qian; Xinxin Ren; Jie Wei; Xue Yang; Yangying Zhou; Zhicheng Gong; Zhijie Xu
Journal:  Front Oncol       Date:  2018-10-23       Impact factor: 6.244

5.  ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC.

Authors:  Hongbo Zhao; Yutang Huang; Jingjing Shi; Yi Dai; Lanxiang Wu; Honghao Zhou
Journal:  Front Pharmacol       Date:  2018-11-20       Impact factor: 5.810

6.  Exosomal Transfer Of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance In NSCLC Through Activating Autophagy.

Authors:  Yuzhu Ma; Daolu Yuwen; Jingwei Chen; Bingfeng Zheng; Jian Gao; Minmin Fan; Wenwen Xue; Yixuan Wang; Wuhao Li; Yongqian Shu; Qiang Xu; Yan Shen
Journal:  Int J Nanomedicine       Date:  2019-10-07

7.  Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines.

Authors:  Susan Heavey; Paul Dowling; Gillian Moore; Martin P Barr; Niamh Kelly; Stephen G Maher; Sinead Cuffe; Stephen P Finn; Kenneth J O'Byrne; Kathy Gately
Journal:  Sci Rep       Date:  2018-01-26       Impact factor: 4.379

Review 8.  MicroRNAs associated with therapy of non-small cell lung cancer.

Authors:  Junmi Lu; Yuting Zhan; Juan Feng; Jiadi Luo; Songqing Fan
Journal:  Int J Biol Sci       Date:  2018-03-10       Impact factor: 6.580

Review 9.  Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer.

Authors:  Hongjing Zang; Jianlun Peng; Weiyuan Wang; Songqing Fan
Journal:  J Cancer       Date:  2017-10-17       Impact factor: 4.207

10.  Trans-3,5,4´-trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498.

Authors:  Min Lu; Bin Liu; Hui Xiong; Fang Wu; Chunhong Hu; Ping Liu
Journal:  J Cell Mol Med       Date:  2019-01-30       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.